Macrogenics Stock News

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therape

ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for t

ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the

Analysts have provided the following ratings for Macrogenics (NASDAQ: MGNX ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 3 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Macrogenics. The company has an average price target of $28.75 with a high of $40.00 and a low of $21.00. Below is a summary of how these 4 analysts rated Macrogenics over the past 3 months. The greater the number of bullish ratings, … Full story available on Benzinga.com

Citi has upgraded MacroGenics (MGNX) to buy from neutral saying the company''s pipeline has "entered undervalued territory."

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared to $0.69 from the ye

Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE: ENV ) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared to $0.69 from the year-ago quarter. The current stock performance of Envestnet shows a 52-week-high of $85.99 and a 52-week-low of $61.00. Moreover, at the end of the last trading period, the closing price was at $72.88. According to B of A Securities, the prior rating for Toll Brothers Inc (NYSE: TOL ) was changed from Underperform to Buy. For the first quarter, Toll Brothers had an EPS of $1.24, compared to year-ago quarter EPS of $0.76. The stock has a 52-week-high of $75.61 and a 52-week-low of $47.17. At the end of the last trading period, Toll Brothers closed at $53.62. For Lockheed Martin Corp (NYSE: LMT ), Wolfe Research upgraded the previous rating of Peer Perform to Outperform. In the fourth quarter, Lockheed Martin showed an EPS of $7.47, compared to $6.38 from the year-ago quarter. The stock has a 52-week-high of $414.45 and a 52-week-low of $324.23.

ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th

The company provided a disappointing Q4 update.

The company provided a disappointing Q4 update.

MGNX earnings call for the period ending December 31, 2021.

MGNX earnings call for the period ending December 31, 2021.